Oric Pharmaceuticals (ORIC) Non-Current Assets (2019 - 2026)

Oric Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $146.5 million for Q1 2026.

• Quarterly Non-Current Assets rose 366.28% year-over-year to $146.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $458.3 million (up 357.07% YoY) and the FY2025 annual result came in at $120.4 million, up 912.65% from the prior year.
• Non-Current Assets was $146.5 million for Q1 2026 at Oric Pharmaceuticals, up from $120.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $146.5 million in Q1 2026 and bottomed at $11.9 million in Q4 2024.
• A 5-year average of $50.7 million and a median of $36.0 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 69.82% — and 2025, when it soared 912.65%.
• Oric Pharmaceuticals' Non-Current Assets stood at $36.7 million in 2022, then climbed by 7.32% to $39.4 million in 2023, then tumbled by 69.82% to $11.9 million in 2024, then surged by 912.65% to $120.4 million in 2025, then increased by 21.68% to $146.5 million in 2026.
• Business Quant data shows ORIC's Non-Current Assets at $146.5 million in Q1 2026, $120.4 million in Q4 2025, and $135.6 million in Q3 2025.